News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex (VRTX) Reports Second-Quarter 2017 Financial Results



7/27/2017 7:54:32 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017. Vertex reiterated its full-year 2017 financial guidance for ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) net revenues and updated its guidance for combined GAAP and non-GAAP R&D and SG&A expenses. The company also reviewed its recent progress toward treating all people with CF, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of CF.

Key financial results include:

Three Months Ended June 30,

%

2017 2016

Change

(in millions, except per share and percentage data)
ORKAMBI product revenues, net $ 324 $ 245 32 %
KALYDECO product revenues, net $

190

$

180

5 %
TOTAL CF product revenues, net $

514

$

426

21 %
GAAP net income (loss) $ 18 $ (65 ) n/a
GAAP net income (loss) per share - diluted $ 0.07 $ (0.26 ) n/a
Non-GAAP net income $ 99 $ 58 71 %
Non-GAAP net income per share - diluted $ 0.39 $ 0.24 63 %

"During the first half of 2017, Vertex has made significant progress throughout the business and in particular, across our CF development programs," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Our progress has been marked by the progression of multiple combination regimens that allow us to treat more people with CF today and to potentially treat up to 90% of patients with this disease in the future."

Financial Highlights


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES